Deep Brain Stimulation and the Leadership of Care

The Resilient Philosopher | D. L. Dantes

“Every day is a great day to learn something new, by removing the excuses and addressing the issues.” – D. L. Dantes

There is a special kind of fear that shows up when the mind becomes the patient. We can accept a cast, stitches, and even a scar because the story is visible and the healing has a timetable we can picture. When the procedure is in the brain, the timetable feels moral, as if the person must return as the same self on demand. Deep brain stimulation, or DBS, confronts that expectation directly. It is a procedure that can restore function by modulating circuits, yet it also reminds me that identity is partly chemistry, partly rhythm, and partly relationship. If I want to write about DBS with integrity, I have to hold the science in one hand and the human in the other.

What DBS Is and What It Is Not

DBS is a form of neuromodulation where thin electrodes are implanted into carefully selected deep brain targets and connected to an implanted pulse generator, usually placed under the skin in the chest. The device delivers controlled electrical pulses intended to influence abnormal brain circuit activity rather than destroy tissue. This distinction matters because DBS is not a lobotomy, not a chemical sedation, and not a personality rewrite by design. It is an adjustable therapy, and the adjustment is part of the treatment rather than evidence the surgery “did not work.” Penn Medicine describes DBS as a treatment option for several movement disorders and emphasizes its programmability over time to reduce symptoms and minimize side effects (Penn Medicine, n.d.). The Parkinson’s Foundation frames DBS the same way for Parkinson’s disease, describing it as a surgical therapy aimed primarily at movement symptoms and certain medication side effects (Parkinson’s Foundation, n.d.). 

The First Weeks: Why “Not Myself Yet” Can Be Normal

Many DBS teams prepare patients for an early period where they may feel off, emotionally reactive, fatigued, or simply not fully like themselves for days or weeks. Early variability can happen even before full programming begins, because surgery, anesthesia, sleep disruption, and pain medications can destabilize attention and mood. One recognized complication after DBS is postoperative delirium, an acute disturbance of attention and awareness that can include confusion, agitation, and perceptual changes. Contemporary work in Parkinson’s cohorts has examined delirium severity and points to factors such as older age and preoperative cognitive vulnerability as meaningful risks (Astalosch et al., 2024). Even when delirium is not present, recovery can still feel like a shifting internal landscape because the brain is trying to regain stable rhythms while the body is healing. The leadership question is not whether this period proves the procedure was wrong, but whether we can recognize the difference between a temporary altered state and a permanent change in character. 

A Better Frame Than “Survival Mode”

I understand the instinct to say the brain goes into protection mode when it detects something new, because it is a story that honors the body’s intelligence. The clinically useful frame, however, is simpler and more accountable, because it connects symptoms to decisions. After DBS, early cognitive and emotional changes are often driven by measurable stressors like inflammation, medication effects, sleep debt, and the demands of recovery. If hallucinations, severe anxiety, or confusion occur, the safest assumption is not that the brain is soothing itself, but that the system is overloaded and needs evaluation. In the postoperative context, fever or new confusion deserves urgent attention because it can signal complications, including infection, and implanted hardware makes infection time-sensitive. This is not a fearful stance. It is a respectful stance toward risk, and it keeps the patient safe while the brain does what it does best, which is adapt over time.

Programming Is the Hidden Half of DBS

DBS is not only a surgery, it is an ongoing calibration process. Penn Medicine notes that neurologists often begin programming about a month after the procedure and may adjust the device over multiple visits to fine-tune benefit and minimize side effects (Penn Medicine, n.d.). In other words, the therapy is tuned, and the tuning is part of the craft. This is why two people with the same diagnosis can have different experiences with DBS, and why early weeks can feel like a moving target. In some cases, stimulation changes can influence mood, energy, and impulse control, not because the person is becoming someone else, but because circuits that regulate movement sit near circuits that regulate emotion and motivation. Clinical reviews have documented stimulation-induced side effects and emphasize that many are addressed through parameter adjustment and clinical follow-up (Zarzycki et al., 2020). The more I learn about DBS, the more I see that the procedure does not eliminate the need for care. It demands more care, more listening, and more humility. 

Where AI Is Already Entering DBS

If I ask where artificial intelligence can help, I start with the most practical bottleneck: programming complexity. DBS creates a high-dimensional decision space where clinicians balance symptom relief, side effects, and changing daily contexts, and patients often pay the price in time and fatigue while the team searches for the best settings. This is the kind of problem where data-driven optimization can reduce trial-and-error and deliver more consistent outcomes across centers. A major milestone in this direction is adaptive DBS, sometimes called closed-loop DBS, where the implanted system senses brain signals and adjusts stimulation rather than delivering a constant preset pattern. On February 24, 2025, Medtronic announced U.S. FDA approval for its BrainSense Adaptive DBS system for people with Parkinson’s disease, a step that moved responsive stimulation from the edge of research toward broader clinical reality (Medtronic, 2025). The American Parkinson Disease Association summarized the same approval as a practical shift from standard DBS to sensing-guided therapy that can adapt based on local field potentials (American Parkinson Disease Association, 2025). This is not a promise that AI will replace clinicians. It is a signal that neuromodulation is becoming a feedback system, and feedback systems are where careful algorithms excel. 

Adaptive DBS and the Promise of Circuit-Level Respect

Adaptive DBS typically uses biomarkers from recorded brain activity to infer when symptoms are likely to worsen and when stimulation should increase or decrease. The point is not that a machine knows the person better than the person knows themselves. The point is that the device can detect a physiologic pattern faster than a human can notice a tremor returning or a stiffness wave creeping in. When this works well, it can reduce periods of under-treatment and over-treatment and smooth out fluctuations that make daily life unpredictable. The technology is still bounded by what we can measure reliably, and that boundary is a feature rather than a flaw. It keeps the work honest, because it forces outcomes to be tested against signals and lived function. If I am serious about “neural AI,” I should value the boring part of science, the part where we prove the control loop is safe, stable, and worth the tradeoffs. In medicine, the highest form of innovation is not novelty. It is reliability.

Connectomics, Targeting, and the Next Layer of Precision

Another frontier is how we choose targets and how we understand which networks are being modulated. DBS has historically relied on anatomy, electrophysiology, and clinical response, but modern imaging and tractography are pushing the field toward circuit-informed targeting. Patient guides from established centers describe waiting for postoperative swelling to resolve and then programming systematically, which reflects an older truth that biology is never instant and accuracy is often earned in phases (Perelman School of Medicine, University of Pennsylvania, 2022). AI can assist by integrating imaging, electrode location, and outcome data to predict which stimulation fields are likely to engage beneficial pathways and avoid problematic ones. This is not about perfection. It is about reducing variance, so fewer patients have to pay for our uncertainty with extra months of adjustment. When I think about leadership, I see an analogy here. Good leadership is the reduction of variance through systems, feedback loops, and the courage to measure what matters. 

What DBS Teaches Me About Work, Dignity, and Patience

A coworker going through DBS is not only a medical story, it is a workplace leadership test. People may show up with slower processing, fatigue, or a shorter emotional fuse during recovery, and the easiest mistake is to treat that as a personality defect. A steadier leader recognizes recovery as a temporary performance context, not a permanent identity. The ethical move is to make space for the human without turning the person into a fragile symbol. That can look like adjusting workload expectations for a defined period, checking in privately rather than speculating publicly, and making it clear that dignity is not conditional on productivity. If the brain can be treated as a system that needs tuning, the workplace can also be treated as a system that needs tuning. We do not have to weaponize weakness to prove we value strength.

A Simple Way to Speak About DBS Without Hype

When I explain DBS to someone who is anxious, I avoid the language of miracles and the language of doom. I say DBS is a therapy that can meaningfully reduce symptoms for the right patient, but it comes with a period of adjustment that can feel strange, and that strangeness is often manageable. I say the device is programmable and that programming is part of the craft, not evidence that the surgery failed. I say that mood and cognition should be monitored with seriousness, because early warning is leadership in clinical form. I say that AI is beginning to help by sensing patterns, adjusting stimulation, and making programming less of a guessing game. Then I stop talking, because reassurance is not always more words. Sometimes reassurance is a calm presence and a willingness to ask the right questions.

Closing Reflection

DBS forces me to reconsider what I mean when I say myself. If the self can be disrupted by fever, restored by sleep, destabilized by surgery, and steadied by carefully tuned pulses, then identity is not a statue. It is a living negotiation between biology and meaning. That does not make the person less responsible for their character, but it does remind me that character is exercised inside a body with limits. The future of DBS will not be defined only by smaller devices or smarter algorithms. It will be defined by whether we build a culture of care around the technology, in clinics and in workplaces, so recovery is met with patience rather than suspicion. The Resilient Philosopher in me does not worship the machine, and I do not fear it either. I measure it by one question: does it reduce suffering while preserving dignity.

D. L. Dantes

References

American Parkinson Disease Association. (2025, February 28). FDA approves new adaptive DBS system. American Parkinson Disease Association. 

Astalosch, M., et al. (2024). Risk factors for postoperative delirium severity after deep brain stimulation surgery in Parkinson’s disease. Journal of Parkinson’s Disease. 

Medtronic. (2025, February 24). Medtronic earns U.S. FDA approval for the world’s first adaptive deep brain stimulation system for people with Parkinson’s. Medtronic Newsroom. 

Parkinson’s Foundation. (n.d.). Understanding deep brain stimulation (DBS) (Video; voiceover by Michael Okun). Parkinson’s Foundation. 

Penn Medicine. (n.d.). Deep brain stimulation. Penn Medicine. 

Penn Medicine. (n.d.). Deep brain stimulation (DBS) for movement disorders (Video). Penn Medicine (YouTube). 

Perelman School of Medicine, University of Pennsylvania. (2022). Deep brain stimulation guide for Parkinson’s disease. Penn Medicine Parkinson’s Disease and Movement Disorders Center. 

Zarzycki, M. Z., et al. (2020). Stimulation-induced side effects after deep brain stimulation: A systematic review. Acta Neuropsychiatrica.